Group 1 - The Cigna Group is recognized as one of the 13 Most Undervalued Dividend Stocks to Buy according to Wall Street Analysts [1] - JPMorgan has maintained an Overweight rating on Cigna following an update regarding its Evernorth unit and a new model for Express Scripts starting in 2027 [2][3] - The new model for Express Scripts eliminates rebates and introduces a point-of-sale approach, allowing customers to pay a net price at the time of dispensing [3][4] Group 2 - The analyst believes the change addresses several regulatory proposals and should "de-risk" Express Scripts' commercial operations [4] - Cigna's shift to a de-linked and rebate-free default offering is seen as a viable approach for the broader business [4] - Cigna has increased its dividend for five consecutive years, with a current dividend yield of 2.02% as of October 29 [4]

Core Insights - The Cigna Group (NYSE:CI) is highlighted as a strong investment opportunity within the defensive healthcare dividend stocks category [1] - Recent analyst upgrades from Goldman Sachs and Wells Fargo have increased interest in Cigna, with Goldman Sachs initiating coverage with a Buy rating and a price target of $370 [3][4] - Cigna has a consistent track record of dividend increases, having raised its dividend for five consecutive years, currently offering a quarterly dividend of $1.51 per share with a yield of 2.00% [5] Analyst Ratings - Goldman Sachs analyst Scott Fidel initiated coverage of Cigna with a Buy rating, citing a significant downturn in the managed care sector and anticipating a recovery phase starting in 2026, particularly in Medicare Advantage [3] - Wells Fargo raised its price target for Cigna from $340 to $354 while maintaining an Equal Weight rating, reflecting an updated outlook for the sector ahead of Q3 2025 earnings [4] Dividend Performance - Cigna has demonstrated strong appeal to income-focused investors by increasing its dividend for five consecutive years, currently providing a quarterly dividend of $1.51 per share [5]

Group 1 - UnitedHealth Group Incorporated (NYSE:UNH) is currently considered a hot stock, with Truist Securities reaffirming its Buy rating and increasing the price target from $310 to $365 on September 9 [1] - The company anticipates that approximately 78% of its membership will be in 4+ Star plans for Payment Year 2027, which is consistent with management's projections and historical trends [2] - UnitedHealth reiterated its goal of achieving at least $16 in adjusted earnings per share for the fiscal year 2025, factoring in the recent acquisition of Amedisys, which may slightly dilute adjusted EPS due to financial expenses and integration costs [3] Group 2 - UnitedHealth Group is a prominent US multinational corporation that provides managed healthcare and insurance services, operating through four main segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx [4]